Novartis | Docwire News

Novartis

Rob DillardVideos | April 28, 2023

DocWire News recently sat down with Shephard Mpofu, M.D., SVP, Chief Medical Officer, Novartis Gene Therapies, to ...

Kaitlyn D’OnofrioRheumatology | September 11, 2023

Pharmaceutical giant Amgen won a ruling in a federal appeals court today against Novartis AG’s Sandoz, preventing the ...

Kaitlyn D’OnofrioRheumatology | August 29, 2019

The U.S. Food and Drug Administration (FDA) has expanded the indication of Eli Lilly and Company’s Taltz (ixekizumab) ...

Kaitlyn D’OnofrioRheumatology | August 16, 2019

Here are the top stories covered by DocWire News this week in the Rheumatology section. In this edition, read about ...

Kaitlyn D’OnofrioRheumatology | August 16, 2019

A U.S. judge ruled in favor of Amgen on the validity of two patents pertaining to the company’s drug Enbrel ...

DocWire News EditorsTelemedicine | May 2, 2023

Pear Therapeutics has recently teamed up with Sandoz, a Novartis branch, to release reSET, the first and only ...

DocWire News EditorsFuture of Medicine | April 25, 2023

This week the Swiss pharmaceutical company Novartis, which has been moving into the rare disease market, said it that ...

Kaitlyn D’OnofrioCardiology | October 22, 2018

The U.S. Food and Drug Administration (FDA) has rejected canakinumab to be used to reduce the risk of cardiovascular ...